Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Non-Current Assets: 2015-2024

Historic Non-Current Assets for Spyre Therapeutics (SYRE) over the last 10 years, with Dec 2024 value amounting to $10,000.

  • Spyre Therapeutics' Non-Current Assets fell 96.96% to $10,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $10,000, marking a year-over-year decrease of 96.96%. This contributed to the annual value of $10,000 for FY2024, which is 96.98% down from last year.
  • Spyre Therapeutics' Non-Current Assets amounted to $10,000 in FY2024, which was down 96.98% from $331,000 recorded in FY2023.
  • Spyre Therapeutics' Non-Current Assets' 5-year high stood at $11.8 million during FY2020, with a 5-year trough of $10,000 in FY2024.
  • For the 3-year period, Spyre Therapeutics' Non-Current Assets averaged around $3.1 million, with its median value being $331,000 (2023).
  • Per our database at Business Quant, Spyre Therapeutics' Non-Current Assets surged by 36.31% in 2020 and then tumbled by 96.98% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Non-Current Assets (Yearly) stood at $11.8 million in 2020, then declined by 6.71% to $11.0 million in 2021, then fell by 19.47% to $8.9 million in 2022, then slumped by 96.28% to $331,000 in 2023, then plummeted by 96.98% to $10,000 in 2024.